COX-2 inhibition and thrombotic tendency: a need for surveillance
Date
2001
Authors
Cleland, L.
James, M.
Stamp, L.
Penglis, P.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Medical Journal of Australia, 2001; 175(20 August 2001):214-217
Statement of Responsibility
Cleland, L G ; James, M J ; Stamp, L K ; Penglis, P S
Conference Name
Abstract
Cyclooxygenase-2 (COX-2) inhibitors belong to a new class of drugs which have anti-inflammatory efficacy similar to that of traditional non-steroidal anti-inflammatory drugs (NSAIDs), but are associated with a reduced incidence of adverse upper gastrointestinal events. Biochemical evidence that COX-2 inhibitors could promote or exacerbate a tendency to thrombosis is supported by recent results from clinical trials and case reports. Two agents in this class, celecoxib and rofecoxib, have been listed on the Pharmaceutical Benefits Scheme (PBS) for very broad indications in chronic arthropathies, suggesting that they will move into widespread community use. It is important to canvass the possibility that use of these agents could be associated with thrombotic events.